Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Study ID
NCT00209638
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase I/II study of this combination in patients with inoperable or with postoperative gastric cancer

Key Dates

Start date
May 31, 2000
Status verified
Apr 2006
Completion
Apr 30, 2003

Study Design

Enrollment
24 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

objective tumor response

Related Studies